Abstract

Purpose: In breast cancer, the EGF receptors host an increasing number of therapeutic targets and the interactive mechanisms of actions of the receptors and their ligands justify investigation of the EGF family as an entity. Experimental design: Paired tissue samples of normal breast tissue and primary breast carcinomas were examined in a prospective study of 163 patients. A third sample was obtained from the paired ipsilateral metastatic lymph node from 58 of these patients. The mRNA expression of four EGF receptors (HER1 - HER4) and 11 activating ligands was quantified with real-time RT-PCR. Results: Expression of HER2, HER3, and HER4 mRNA was upregulated in primary carcinomas compared to normal breast tissue while HER1 was downregulated. The mRNA expression of HER3 and HER4 differed between primary breast carcinomas and lymph node metastases whereas there was no difference in the expression of HER1 and HER2. The combination of low HER3 and low HER4 expression in the primary carcinoma was significantly more frequent in lymph node-negative patients as compared to lymph node positive patients. Distinct correlation patterns of the receptors and their corresponding activating ligands appeared in both normal breast tissue and in carcinomas, notably for the HER3 and HER4 receptors and their 3 specific ligands: HB-EGF, NRG2, and NRG4. Conclusion: HER2, HER3, and HER4 showed increased mRNA expression in carcinomas and were positively correlated to each other and to specific activating ligands. Furthermore, low HER3 and HER4 expression in the carcinomas correlated to the absence of lymph node metastases.

Highlights

  • In breast cancer, the family of epidermal growth factor (EGF) receptors is the target of an increasing number of therapeutic drugs [1] [2]

  • We examined the mRNA expressions of the four EGF receptors (HER1-HER4) including the 2 HER4 isomeric splicevariants (CYT1 and CYT2), and 11 of their activating ligands in paired samples of normal breast tissue and carcinoma specimens from 163 patients

  • HER1 showed a significantly higher mRNA expression in the normal breast tissue specimens compared with the carcinomas

Read more

Summary

Introduction

The family of epidermal growth factor (EGF) receptors is the target of an increasing number of therapeutic drugs [1] [2]. The biomarkers decisive for targeted treatment are evaluated in the primary breast carcinoma the target is the metastatic cells and the minimal residual disease. Axillary lymph node metastases are the detectable clinical manifestation of metastatic cells. The primary route for the metastatic spread of breast carcinoma is via the lymphatic system, and the axillary lymph node status remains the best prognostic factor [3] [4]. Assuming that the lymph node metastases represent a migrated fraction of the primary tumor cells, the metastatic cells would, conceivably, share an identical molecular profile [5]. Recent research has shown that the heterogeneity and clonal diversity seen in breast cancer contradict this notion [6]-[11]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call